Replies to post #287930 on Anavex Life Sciences Corp (AVXL)

[falconer66a]

The PDD data will speak for themselves.

What would you like to see as an amendment to the PDD results that we have seen so far.

I have no interest in seeing any "amendments" to the Parkinson's disease dementia results. I'm just eager to see the same data that the FDA poohbahs will scrutinize. Exactly when those appear is, like most of the presumed or anticipated clinical data release dates for any of the Anavex clinical trials, always mysterious.

But, sooner or later, all of the on-going blarcamesine human trials will conclude and the details of their results will be open for scrutiny.

As with all of the previous human studies of blarcamesine, I expect all of them to provide solid, favorable results. Simply, whether pre-clinically in murines (lab rodents) or in actual humans in clinical trials, blarcamesine has never been shown to have disqualifying adverse events (side effects); while at the same time each trial has yielded positive, favorable therapeutic outcomes. There have been sufficient blarcamesine trials so as to discount the likelihood of new safety concerns or efficacy failures. Blarcamesine has a proven, long record of both safety and therapeutic efficacy. There is no known reason these clinical outcomes will not continue.

Anavex hasn't arbitrarily chosen a few CNS diseases to test their drug on, hoping that, somehow, it might work. They've done the detailed preclinical work in model murines with the human CNS disease genetics or biochemistries. Missling and his compatriots at Anavex know what they have, how it works, and for which diseases it will be efficacious. Just a matter of time and clinical trials to prove all of this to the Food and Drug Administration.

I've known all of this for four or five years now. From the start of my interest in Anavex (when I bought my first AVXLs), I've always projected that the company's science can't mature, be recognized and fully at play in the market until at least 2023. Until then, I can wait (profitably).